What is the purpose of this study?

To find out the safety and efficacy of iberdomide with dexamethasone and daratumumab (IberDd) or bortezomib and dexamethasone (IberVd).

In this video:

Dr. Neils van de Donk discussed the safety and efficacy of the two triplet regimens in patients with relapsed/refractory multiple myeloma – 27 patients were assigned to IberDd and 23 were assigned to IberVd.

Conclusion:

Triplet combinations consisting of iberdomide with dexamethasone and daratumumab or bortezomib and dexamethasone  demonstrated favorable tolerability profiles and promising clinical activity in patients with heavily pretreated multiple myeloma.

ASH 2020: Abstract 724

Neils van de Donk, MD 

Niels van de Donk, MD, PhD, is a Hematologist at the VU University Medical Center, Amsterdam, Netherlands.